Cargando…
Remdesivir impairs mouse preimplantation embryo development at therapeutic concentrations
Remdesivir (RDV) is the first antiviral drug to be approved by the US Food and Drug Administration for the treatment of COVID-19. While the general safety of RDV has been studied, its reproductive risk, including embryotoxicity, is largely unknown. Here, to gain insights into its embryotoxic potenti...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122741/ https://www.ncbi.nlm.nih.gov/pubmed/35605700 http://dx.doi.org/10.1016/j.reprotox.2022.05.012 |